18 closest matches · ranked by relevance
Homocystinuria
Primary: Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient Homocystinuria (CBSDH) Pre and Post Taurine…
Hyperhomocysteinemia · Obesity
Primary: Changes of Homocysteine Level — -0.68; -1.35 µmol/L — p=0.05
Cardiovascular Abnormalities
Primary: Change in Plasma Total Homocysteine Concentration (tHcy) — 1.9; 2.7; 0.5 mcmol/L — p=<0.05
Schizophrenia
Primary: Correlation Between Baseline Blood Folate and Smoking Status — 14.6; 14.6; 14.2; 614 nanograms per milliliter
Kidney Disease · Albuminuria
Primary: The Primary Outcome Measure is Level of Albuminuria. — 927.9; 897.1 ratio
Homozygous Familial Hypercholesterolemia
Primary: Number of LDLR Gene Mutations — 7 gene mutations
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
Cardiovascular Risk Factor
Primary: Change From Baseline in Insulin Sensitivity at 4 Weeks — 0.28; -0.29 Calculated Ratio - No units
Chronic Kidney Disease · Cardiovascular Disease · Death
Primary: Recurrent or de Novo Arteriosclerotic Cardiovascular Disease (CVD) Defined as the Occurrence of Non-fatal or Fatal Arteriosclerotic Outcomes Including Coronary Heart…
BH4 Deficiency · Hyperphenylalaninemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 2; 4; 3 Participants
Disorder of Vitamin B12
Primary: Change in Holo-transcobalamin — 124 pmol/L
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Obesity · Dysglycemia
Primary: Fasting and 2 Hour Glucose Levels, Comparing Baseline and 12 Weeks. — -5; 3; 7; -4 mg/dl
Peroxisome Biogenesis Disorders
Primary: Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid — 0.180; 0.188 ratio
Colorectal Cancer
Primary: Changes of Cytosine Modification in TMPRSS2 (5-mC at cg16371860) by Magnesium Treatment Versus Placebo — 0.007; -0.001; 0.012; -0.002 units on CpG sites — p=<0.05
Arsenic Metabolites Measured in Urine
Primary: Change in Urinary % Monomethyl Arsenic — 2.4; 0.24; -0.06; -3.2 percentage of total urinary arsenic
Hyperinsulinism-Hyperammonemia Syndrome
Primary: Tolerability of Vitamin E Based on Responses to a Subject/Parent-reported Symptom Questionnaire After Vitamin E Supplementation Compared to Baseline — 2 Participants
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants